These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7965504)

  • 1. Diagnosis and treatment of cytomegalovirus disease in pediatric renal transplant recipients.
    Burd RS; Gillingham KJ; Farber MS; Statz CL; Kramer MS; Najarian JS; Dunn DL
    J Pediatr Surg; 1994 Aug; 29(8):1049-54. PubMed ID: 7965504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
    Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and morbidity of cytomegalovirus disease associated with a seronegative recipient receiving seropositive donor-specific transfusion and living-related donor transplantation. A multicenter evaluation.
    Weir MR; Henry ML; Blackmore M; Smith J; First MR; Irwin B; Shen S; Genemans G; Alexander JW; Corry RJ
    Transplantation; 1988 Jan; 45(1):111-6. PubMed ID: 2827352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human cytomegalovirus and kidney transplantation: a clinician's update.
    De Keyzer K; Van Laecke S; Peeters P; Vanholder R
    Am J Kidney Dis; 2011 Jul; 58(1):118-26. PubMed ID: 21684438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of ganciclovir for cytomegalovirus infection.
    Nevins TE; Dunn DL
    J Am Soc Nephrol; 1992 Jun; 2(12 Suppl):S270-3. PubMed ID: 1323340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.
    Bodro M; Sabé N; Lladó L; Baliellas C; Niubó J; Castellote J; Fabregat J; Rafecas A; Carratalà J
    Liver Transpl; 2012 Sep; 18(9):1093-9. PubMed ID: 22532316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report.
    Ciszek M; Mucha K; Foroncewicz B; Chmura A; Pączek L
    Ann Transplant; 2014 Jan; 19():60-3. PubMed ID: 24481271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus as a risk factor in living-related renal transplantation. A prospective study.
    Pollak R; Barber PL; Prusak BF; Mozes MF
    Ann Surg; 1987 Mar; 205(3):302-4. PubMed ID: 3030201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus infection: its incidence and management in cytomegalovirus-seropositive living related liver transplant recipients: a single-center experience.
    Wadhawan M; Gupta S; Goyal N; Vasudevan KR; Makki K; Dawar R; Sardana R; Lal N; Kumar A
    Liver Transpl; 2012 Dec; 18(12):1448-55. PubMed ID: 22903934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation.
    Arthurs SK; Eid AJ; Pedersen RA; Kremers WK; Cosio FG; Patel R; Razonable RR
    Clin Infect Dis; 2008 Mar; 46(6):840-6. PubMed ID: 18260785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.
    George MJ; Snydman DR; Werner BG; Griffith J; Falagas ME; Dougherty NN; Rubin RH
    Am J Med; 1997 Aug; 103(2):106-13. PubMed ID: 9274893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism in programmed cell death 1 gene is strongly associated with lung and kidney allograft survival in recipients from CMV-positive donors.
    Forconi C; Gatault P; Miquelestorena-Standley E; Noble J; Al-Hajj S; Guillemain R; Stern M; Hoffmann T; Prat L; Suberbielle C; Masson E; Cesbron-Gautier A; Gaudy-Graffin C; Goudeau A; Thibault G; Ivanes F; Guibon R; Kazma I; Lebranchu Y; Büchler M; Magnan A; Halimi JM; Baron C
    J Heart Lung Transplant; 2017 Mar; 36(3):315-324. PubMed ID: 27751774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transplanting kidneys from CMV-seropositive donors to CMV-seronegative recipients is not associated with poorer renal allograft function or survival.
    McLaughlin K; Sandhu S; Wu C; Muirhead N; Hollomby D; Jevnikar A
    Nephrol Dial Transplant; 2005 Jan; 20(1):176-80. PubMed ID: 15572381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of cytomegalovirus infection by weekly surveillance after renal transplant: analysis of cost, rejection and renal function.
    Geddes CC; Church CC; Collidge T; McCruden EA; Gillespie G; Matthews E; Hainmueller A; Briggs JD
    Nephrol Dial Transplant; 2003 Sep; 18(9):1891-8. PubMed ID: 12937240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T; Borges K; Williams A; Banh T; Vasilevska-Ristovska J; Allen U; Parekh RS; Hébert D
    Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME; Snydman DR; Griffith J; Ruthazer R; Werner BG
    Ann Intern Med; 1997 Feb; 126(4):275-9. PubMed ID: 9036799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
    Reischig T; Jindra P; Svecová M; Kormunda S; Opatrný K; Treska V
    J Clin Virol; 2006 Jun; 36(2):146-51. PubMed ID: 16531113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late cytomegalovirus infection in children: High incidence of allograft rejection and hepatitis in donor negative and seropositive liver transplant recipients.
    Verma A; Palaniswamy K; Cremonini G; Heaton N; Dhawan A
    Pediatr Transplant; 2017 May; 21(3):. PubMed ID: 28134467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival.
    Sagedal S; Hartmann A; Nordal KP; Osnes K; Leivestad T; Foss A; Degré M; Fauchald P; Rollag H
    Kidney Int; 2004 Jul; 66(1):329-37. PubMed ID: 15200441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.